News & Articles

SEATTLE, Feb. 7, 2017 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC. Camargo will be providing end-to-end regulatory consulting and strategic development services for Impel's pipeline of drug-device combination...

When: January 10, 2016 – January 11, 2016 (all-day) Where: San Francisco, CA, USA Who: Impel CEO, John Hoekman will be attending the 35th annual JPM Healthcare Conference ...

Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents most compounds from reaching the...

On April 8th, Impel's director of business development, Paul Jenkins, will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Nasal Drug Delivery Conference in London. His presentation is on April 8 at 11:30 am in the Nose-to-brain Transport session....